Overcoming therapy resistance in pancreatic cancer: New insights and future directions

Area of Science:

• Oncology
• Cancer Research
• Translational Medicine

Background:

• Pancreatic adenocarcinoma (PDAC) presents a critical challenge in oncology, projected to be the second leading cause of cancer-related mortality by 2030.
• Therapy failure and inherent resistance to standard treatments contribute to PDAC's dismal prognosis and low survival rates.
• Pancreatic tumors exhibit poor responsiveness to conventional interventions like chemotherapy, radiotherapy, and targeted therapies.

Purpose of the Study:

• To review the fundamental hallmarks of therapy resistance in pancreatic cancer.
• To discuss current strategies designed to overcome resistance mechanisms and re-sensitize PDAC cells to therapeutic agents.
• To provide insights into emerging advancements in drug discovery, nanomedicine, and disease models for future research.

Main Methods:

• Literature review of pancreatic adenocarcinoma therapy resistance.
• Analysis of current therapeutic strategies and their limitations.
• Exploration of recent developments in drug discovery, nanomedicine, and preclinical models.

Main Results:

• PDAC is characterized by multiple intrinsic and acquired resistance mechanisms.
• Existing therapies often fail due to tumor heterogeneity and complex signaling pathways.
• Novel approaches are emerging to target resistance pathways and enhance treatment efficacy.

Conclusions:

• Understanding PDAC therapy resistance is crucial for improving patient outcomes.
• Innovative strategies in drug discovery and nanomedicine hold promise for overcoming treatment challenges.
• Advancements in disease models are essential for preclinical validation and future therapeutic development.